SCHEMBL839528

SCHEMBL839528

CC(=O)N(C(C)=O)[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
MAPT P10636 2/20 0.68
POLB P06746 2/20 0.68
APAF1 O14727 1/20 0.68
RECQL P46063 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.62
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 1/20 0.60
MPO P05164 1/20 0.60
TSHR P16473 1/20 0.60
BLM P54132 1/20 0.60
PMP22 Q01453 1/20 0.60
HIF1A Q16665 1/20 0.60
ALOX15 P16050 1/20 0.57
DNMT1 P26358 3/20 0.53
ACE P12821 3/20 0.53
GAA P10253 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839527 1.00 KDM4E (0.68) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL1162357 0.89 SMN1; SMN2 (0.65) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL1162356 0.89 SMN1; SMN2 (0.65) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL29751962 0.88 KDM4E (0.63) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL31018783 0.88 KDM4E (0.63) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL31018781 0.88 KDM4E (0.63) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL29773596 0.87 KDM4E (0.61) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL29773608 0.87 KDM4E (0.61) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL4189542 0.87 KDM4E (0.61) KDM4EMAPTPOLBAPAF1RECQL
SCHEMBL4189543 0.87 KDM4E (0.61) KDM4EMAPTPOLBAPAF1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN claimed
EP-4319795-A1 PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS Avantor Performance Materials, LLC (US) 2024-02-14 EP disclosed
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN disclosed
CN-117355321-A Performance enhancing excipients and methods for reducing viscosity and improving stability of biological agents 安万托特性材料股份有限公司 2024-01-05 CN disclosed
US-8143211-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2012-03-27 US disclosed
US-20080287346-A1 Bioactive peptides SVENDSEN JOHN SIGURD 2008-11-20 US disclosed
US-7439228-B2 Bioactive peptides LYTIX BIOPHARMA AS (NO) 2008-10-21 US disclosed
US-6890902-B2 Cytotoxic modified lactoferrin peptides ALPHARMA AS (NO) 2005-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287346-A1 Bioactive peptides VIP, NGLY1, IAPP KDM4E 4285/4885MAPT 4505/4885POLB 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.